HIGH END CELLOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The high end cellomics market size is expected to reach US$ 7.20 Bn by 2030, from US$ 3.90 Bn in 2023, at a CAGR of 9.1% during the forecast period. High end cellomics involves the study of cells and their properties using advanced techniques like microscopy, flow cytometry, mass spectrometry, etc. It enables the analysis of cellular physiology at the single cell level. The rising incidence of chronic diseases like cancer is driving the market growth.

The high end cellomics market is segmented based on product, application, technology, end user and region. Based on product type, the market is segmented into instruments, consumables & reagents, and software & services. The instruments segment is expected to account for the largest share in 2023 owing to the launch of advanced high end instruments like confocal microscopes, flow cytometers, etc.

High End Cellomics Market Regional Insights:

• North America is expected to be the largest market for high end cellomics during the forecast period, accounting for over 40.5% of the market share in 2023. The growth of the market in North America is attributed to high healthcare expenditure, presence of key players, and growing research on cellomics. For instance, in June 2021, Thermo Fisher Scientific Inc., a major biotechnology company based in the U.S., announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera. The Attune CytPix collects high-performance fluorescent flow cytometry data from cells while also recording high resolution brightfield images, allowing users to match images with flow cytometry data to better understand the morphology and quality of the cells.
• Europe market is expected to be the second largest market for high end cellomics, accounting for over 28.7% of the market share in 2023. The growth of the market in Europe is attributed to increasing research funding and rising incidence of chronic diseases.
• Asia Pacific market is expected to be the fastest-growing market for high end cellomics, with a CAGR of over 15% during the forecast period. The growth of the market in Asia Pacific is attributed to the improving healthcare infrastructure, growing biopharma sector, and increasing focus on precision medicine.

Figure 1. Global High End Cellomics Market Share (%), by Region, 2023

To learn more about this report, request a free sample copy

Analyst’s Views

The global high-end cellomics market is poised for robust growth, driven by the ever-expanding applications of advanced cellular analysis technologies across pharmaceutical research, personalized medicine, and life sciences. Continuous innovation in high-content screening, single-cell analysis, and 3D cell culture, coupled with the integration of artificial intelligence and the increasing focus on personalized therapies, is propelling the market forward. As the demand for more precise drug discovery tools and in-depth understanding of cellular biology intensifies, the high-end cellomics market is likely to witness sustained expansion. However, challenges related to cost, data management, and complex analysis must be addressed to unlock the full potential of these technologies. Regional variations in market dynamics and evolving regulatory environments further add complexity to the global landscape, making a comprehensive understanding of this market crucial for both established and emerging players.

High End Cellomics Market Drivers:

• Technological Advancements in Cellomics Techniques: Significant technological advancements are being made in cellomics techniques, which is driving the growth of the high end cellomics market. Companies are developing advanced high-resolution microscopes, enhanced workflow cytometry systems, and innovative imaging software that allow more in-depth study of cell morphology, functionality, and behavior. For instance, expansion microscopy is an emerging technique that enables imaging subcellular structures at resolutions better than 60 nm. Similarly, multiplex immunofluorescence, imaging mass cytometry, and other cytomics methods are being used for high-parameter single cell analysis. These advanced technologies provide researchers tools to gain valuable insights not possible previously. For instance, in May 2023, Deepcell, a company that specializes in single-cell research powered by Artificial Intelligence (AI), announced its launch of the REM-I Platform, a high-dimensional platform for cell morphology analysis and sorting that includes the Axon data suite, Human Foundation Model, and benchtop equipment REM-I. The REM-I Platform, which combines single cell imaging, sorting, and high-dimensional analysis, will spur the creation of novel approaches to discovery in a variety of disciplines including developmental biology, cancer biology, and stem cell biology.
• Application in Drug Discovery and Personalized Medicine: The application of high end cellomics in drug discovery and development is contributing to market growth. Pharmaceutical companies are increasingly adopting high content screening and high-throughput cellomics for lead compound identification and toxicity testing. Moreover, cellomics aids in the development of personalized therapies by identifying specific biomarkers and drug targets based on an individual’s molecular profile. Companies are also utilizing patient-derived organoids, spheroids, and other in-vitro models in cellomics early in preclinical studies to make drug discovery more focused, rapid, and effective.
• Rising Incidence of Chronic and Infectious Diseases: The rising prevalence of chronic and infectious diseases like cancer, autoimmune disorders, and COVID-19 is driving the cellomics market growth. As per the World Health Organization (WHO), in 2020, 10 million people died of cancer accounting for nearly one in six deaths worldwide. Cellomics facilitates the understanding of disease pathogenesis at cellular and molecular level, which helps identify new diagnostic biomarkers and therapeutic targets. Moreover, cellomics is being applied to develop stem cell therapies, immunotherapies, and other advanced treatments for cancer and degenerative diseases.
• Investments in Life Science Research: Increased R&D spending and investments in life sciences globally has positively impacted the global high end cellomics market. According to estimates by the UNESO Institute for Statistics, global R&D reached a record high of almost US$ 1.7 trillion. Government and private funding in fundamental cell biology and translational medical research has grown. Many major initiatives like the Human Cell Atlas Project and NIH’s BRAIN initiative are underway. This provides resources for cellomics research and raises its adoption in clinical and biomedical applications.

High End Cellomics Market Opportunities:

• Emerging Markets: Developing countries present significant opportunities for the growth of the high end cellomics market. Countries like China, India, Brazil, and others are expected to witness the increased adoption of cellomics technologies driven by improving R&D infrastructure, investments in biomedicine, and government policy support. For instance, China has seen the rapid development of preclinical drug discovery programs integrated with high content imaging and high-throughput screens. Companies are also expanding their distribution networks in these high potential markets. For instance, Asia contributed for 57 percent of global GDP growth between 2015 and 2021, according to McKinsey & Company, a worldwide management consulting firm. Asia provided 42 percent of global GDP (at purchasing power parity) in 2021, more than any other region.4. It solidified its position as a significant player in global commerce. Asia contributed approximately 53% of global goods trade in 2021 and 59% of trade growth between 2001 and 2021.
• Process Automation and Artificial Intelligence (AI): Automation and AI are opening new prospects in cellomics. Advanced robotic liquid handling platforms and machine learning algorithms are enabling automated high throughput sample preparation, staining, image acquisition, and analysis. Companies like Recursion Pharmaceuticals and Healx are using AI for phenotypic screening. Cloud-based solutions improve data management and accessibility. Implementation of lab automation will increase productivity, improve standardization, and support the growth of the cellomics field. For instance, in July 2023, Recursion, a clinical stage TechBio company, announced a US$ 50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). With this investment, the company plans to accelerate development of its AI foundation models for biology and chemistry, which in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using the NVIDIA cloud service.
• Point-of-Care Testing: Point-of-care cellomics testing presents opportunities for market expansion. Portable and easy to use cellomics tools that can be utilized in clinical settings are being developed. For example, cell morphology analyzers for cancer screening, miniaturized imaging cytometry for CD4 counting in HIV. Point-of-care cellomics can make precision diagnostics more accessible and support treatment monitoring and companion diagnostics. Players are focused on developing integrated microfluidic solutions for POC testing.
• Growing Use of Organ-on-a-Chip Models: The increasing use of organ-on-a-chip models in cellomics research provides growth opportunities. These are microfluidic cell culture devices with living cells arranged to mimic organ physiology in vitro. Companies like Emulate, TissUse, and CN Bio are offering organ chips for lung, kidney, intestine, brain, etc. These advanced organoid models enable studying complex cell interactions, disease pathways, and toxicity. Cellomics technologies like high content imaging provide detailed functional analysis of organ chips for preclinical drug testing.

High End Cellomics Market Trends:

• Convergence with Single-cell Analysis: A major trend shaping the global high end cellomics market is in convergence with single cell research tools. Single cell genomic, proteomic, and metabolomic analyses are being integrated with high content imaging to gain the multidimensional view of individual cells. Companies like NanoString and 10x Genomics offer platforms that combine single cell RNA sequencing or proteomics with spatial mapping. The spatial context provided by cellomics complements omics data for comprehensive analysis. For instance, in December 2022, 10x Genomics, a life sciences company, announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of subcellular-resolution targeted spatial profiling of genes and proteins. The platform consists of an adaptable and user-friendly tool, a wide selection of carefully chosen, high-quality panels that are customizable, and Xenium Explorer, a user-friendly program for interactive data visualization.
• Biopharma Industry Adoption: Pharmaceutical and biotechnology companies are increasingly adopting cellomics tools to enhance drug R&D programs. Many top biopharma companies have invested in building in-house cellomics capabilities and centers for high-throughput assays. Outsourcing to contract research organizations offering cellomics services is also rising. Strong industry demand will likely make biopharma the fastest growing end-use segment during the forecast period. For instance, on October 31, 2023, Altasciences, an integrated drug development solution company, announced the completion of the expansion of a new state-of-the-art laboratory in Columbia, Missouri, U.S. The newly expanded, 8,000-square-foot space includes a vast range of services including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
• Cell-based Therapy Development: The application of cellomics in development, manufacturing, and testing of cell therapies is rising. Cellomics aids in the optimization of cell culture protocols and characterization of cell phenotype. Moreover, high content analysis is utilized for product safety and potency testing as per regulatory guidelines. Companies developing CAR T-cell, stem cell, and regenerative therapies are actively adopting cellomics, thus contributing to its market expansion.
• Adoption of AI and Machine Learning: AI and machine learning are positively disrupting the global high end cellomics market. Researchers are applying deep learning algorithms to automate image processing and analysis. Companies like Stilla and PathAI offer machine learning powered software for cytological diagnosis and profiling. Moreover, generative neural networks are being leveraged to predict cell morphology changes and simulate complex cell behavior in-silico. The integration of AI in cellomics workflows will continue during the forecast period.

High End Cellomics Market Restraints:

• High Cost of Instruments and Consumables: The high capital and operational costs associated with advanced high-end cellomics instruments is restraining the market growth. Flow cytometers, automated microscopes, and imaging cytometers cost between US$ 80,000 to US$ 150,000. Along with instrument costs, consumables like assays, probes, and microplates also represent a major expense for end users. This hampers adoption among academic labs and smaller research outfits with budget constraints. For instance, the price of the Confocal Microscope ranges anywhere from under US$ 750 to over US$ 89,000, depending on its features.
• Complex Data Analysis: Data analysis poses a major challenge in high content cellomics research and is limiting the market expansion. Lack of universal analytical approaches and complex proprietary software hampers data interpretation. Moreover, cellomics produces very large multidimensional datasets requiring specialized bioinformatics expertise, which is lacking among many end users. Availability of user-friendly analytical solutions will be a key to drive broader adoption.
• Lengthy Product Development Cycles: The typically long product development cycles of around 3-5 years in the global high end cellomics market acts as market restraint. Bringing sophisticated instruments and reagents kits from proof-of-concept to commercial launch involves substantial R&D investments. Delay in product launches due to internal resource constraints or regulatory hurdles slows market growth. Companies are implementing strategies to accelerate product commercialization through partnerships.

Recent Developments:

New product launches:

• In January 2023, Axion BioSystems, a life science company, announced the launch of the Omni Pro 12 to its Omni live-cell imaging product range. The new platform gives scientists and drug developers doing live-cell imaging tests more flexibility and efficiency. It has integrated robotics and a multiplate architecture that works with any conventional incubator.
• In February, 2023, Discover Echo, a BICO subsidiary and a leading developer of revolutionary microscopy and imaging technologies, has introduced its newest product: the Echo Confocal microscope, a sophisticated imaging system that delivers high-resolution pictures of biological material with excellent clarity and detail
• In May 2023, BD, a global medical technology company, announced the worldwide commercial launch of a new-to-the-world cell sorting instrument that incorporates two significant technologies: spectral flow cytometry and real-time imaging technology, allowing researchers to uncover previously invisible information about cells in traditional flow cytometry experiments

Acquisitions and partnerships:

• In January 2023, Bruker Corporation, a producer of scientific equipment for materials and molecular research, has announced that it has acquired ACQUIFER Imaging GmbH, a company that specializes in big-data management systems for high-content microscopy and bioimaging. High-performance on-premise processing, secure storage, and networking technologies are added by this purchase to enhance Bruker's high-information-content advanced fluorescence microscopy imaging solutions, namely light-sheet and super-resolution microscopy products.
• In August 2023, BioSkryb Genomics, a single-cell analysis company, announced a collaboration with Research Instruments Pte Ltd, a premier distributor of genomic and life science research products in Southeast Asia, to distribute BioSkryb's ResolveDNA and ResolveOME single cell amplification tools throughout Singapore and Southeast Asia
• In February 2022, Waters Corporation, a global company focused on analytical instruments and software, announced that it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass Spectrometry (CDMS) technology and services to broaden Waters Corporation's application in cell and gene therapy

Figure 2. Global High End Cellomics Market Share (%), by Product Type, 2023

To learn more about this report, request a free sample copy

Top companies in High End Cellomics Market:

• Thermo Fisher Scientific
• Danaher
• PerkinElmer
• BD
• Bio-Rad Laboratories
• Agilent Technologies
• Illumina
• Luminex
• Merck KGaA
• GE Healthcare
• Bruker
• Nanostring Technologies
• 10x Genomics
• Fluidigm
• Celsee
• Berkeley Lights
• Miltenyi Biotec
• Bionano Genomics
• Bio-Techne
• Sphere Fluidics

Definition: High end cellomics involves the study of cells, their functions and properties using advanced techniques and instrumentation. It encompasses various analytical methods like microscopy, flow cytometry, mass spectrometry, next generation sequencing, etc. for high-content and high-throughput cell analysis. Cellomics allows researchers to study cell populations and single cells in detail to understand cell differentiation, proliferation, morphology, and biomarker expression. It has applications in disease research, drug discovery & development, personalized medicine, and development of cell-based therapies. High end cellomics provides researchers and scientists tools to delve deep into cell physiology and behavior and understand inter-cellular communications and interactions. With advanced high-end instruments, it is possible to study cell heterogeneity, conduct live cell imaging, assess cytotoxicity, and analyze complex cell models like organoids. In summary, high end cellomics empowers the study of cell biology at an unprecedented resolution which was earlier not possible with traditional methods.